The impacts of the NOD2 agonist MDP and the PD-1 inhibitor on monocyte transformation and recruitment to the AD brain are diagrammatically illustrated in Figure 1; however, certain phenomena remain unexplored and necessitate further elucidation. This evidence concerns the gene NOD2 and Alzheimer disease.